Sentiment-Signal
14,2
Stark Bearisch
Composite Score (0–100)
Insider (25%)
0
Keine Insider-Käufe
Institutionell (22,5%)
0
Keine neuen Positionen
Aktivist (12,5%)
0
Kein 13D/13G
Risikofreier Zins (T-Bills): 3,70% (Stand: 31.03.2026)
Score-Verlauf (90 Tage)
Stammdaten
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
Unternehmen & Branche
| Name | Edgewise Therapeutics, Inc. |
|---|---|
| Ticker | EWTX |
| CIK | 0001710072 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 3,34 Mrd. USD |
| Beta | 0,25 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -167,795,000 | -1.63 | 552,603,000 | 522,257,000 | |
| 2025-09-30 | 10-Q | -40,666,000 | -0.39 | 583,466,000 | 558,647,000 | |
| 2025-06-30 | 10-Q | -36,115,000 | -0.34 | 613,334,000 | 589,071,000 | |
| 2025-03-31 | 10-Q | -40,798,000 | -0.43 | 454,391,000 | 429,719,000 | |
| 2024-12-31 | 10-K | -133,813,000 | -1.45 | 486,817,000 | 459,216,000 | |
| 2024-09-30 | 10-Q | -34,129,000 | -0.36 | 511,282,000 | 488,877,000 | |
| 2024-06-30 | 10-Q | -31,497,000 | -0.34 | 531,647,000 | 510,474,000 | |
| 2024-03-31 | 10-Q | -28,525,000 | -0.33 | 553,806,000 | 534,941,000 | |
| 2023-12-31 | 10-K | -100,163,000 | -1.57 | 340,035,000 | 318,830,000 | |
| 2023-09-30 | 10-Q | -25,713,000 | -0.41 | 311,364,000 | 290,427,000 | |
| 2023-06-30 | 10-Q | -21,469,000 | -0.34 | 330,625,000 | 311,455,000 | |
| 2023-03-31 | 10-Q | -22,838,000 | -0.36 | 346,400,000 | 328,840,000 | |
| 2022-12-31 | 10-K | -67,640,000 | -1.26 | 367,101,000 | 346,716,000 | |
| 2022-09-30 | 10-Q | -17,498,000 | -0.34 | 377,153,000 | 361,404,000 | |
| 2022-06-30 | 10-Q | -16,067,000 | -0.32 | 257,399,000 | 246,355,000 | |
| 2022-03-31 | 10-Q | -14,660,000 | -0.30 | 272,745,000 | 260,356,000 | |
| 2021-12-31 | 10-K | -42,813,000 | -1.14 | 285,233,000 | 274,383,000 | |
| 2021-09-30 | 10-Q | -12,949,000 | -0.26 | 294,448,000 | 285,399,000 | |
| 2021-06-30 | 10-Q | -10,353,000 | -0.21 | 303,493,000 | 296,754,000 | |
| 2021-03-31 | 10-Q | -6,815,000 | -4.37 | 311,245,000 | 306,394,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-01 | Donovan Joanne M. | Officer, CMO | Open Market Sale | -28,662 | 32.31 | -926,095.02 | -156,7% | |
| 2026-03-31 | Donovan Joanne M. | Officer, CMO | Open Market Sale | -21,338 | 32.12 | -685,308.28 | -116,0% | |
| 2026-03-27 | Donovan Joanne M. | Officer, CMO | Open Market Sale | -6,735 | 30.98 | -208,635.48 | -35,3% | |
| 2026-03-27 | Donovan Joanne M. | Officer, CMO | Open Market Sale | -9,623 | 30.98 | -298,099.37 | -50,5% | |
| 2026-01-21 | Edris Badreddin | Director | Open Market Sale | -10,463 | 29.44 | -308,030.72 | -52,1% | |
| 2026-01-21 | Edris Badreddin | Director | Open Market Sale | -7,605 | 29.44 | -223,891.20 | -37,9% | |
| 2026-01-21 | Edris Badreddin | Director | Open Market Sale | -13,690 | 29.44 | -403,033.60 | -68,2% | |
| 2026-01-21 | Edris Badreddin | Director | Open Market Sale | -17,236 | 29.44 | -507,427.84 | -85,9% | |
| 2026-01-21 | Edris Badreddin | Director | Open Market Sale | -66,477 | 29.44 | -1,957,082.88 | -331,2% | |
| 2025-11-12 | Russell Alan J | Director, Officer, Chief Scientific Officer | Open Market Sale | -100,000 | 21.12 | -2,112,450.00 | -357,5% | |
| 2025-11-11 | Fox Jonathan C | Director | Open Market Purchase | 10,700 | 18.64 | 199,403.06 | +33,7% | |
| 2025-08-26 | Russell Alan J | Director, Officer, Chief Scientific Officer | Open Market Sale | -100,000 | 14.60 | -1,459,760.00 | -247,1% | |
| 2025-08-12 | Carruthers R Michael | Officer, Chief Financial Officer | Open Market Sale | -1,428 | 13.39 | -19,124.35 | -3,2% | |
| 2025-08-12 | Donovan Joanne M. | Officer, CMO | Open Market Sale | -2,862 | 13.39 | -38,329.05 | -6,5% | |
| 2025-05-02 | Donovan Joanne M. | Officer, CMO | Open Market Sale | -5,187 | 16.45 | -85,347.94 | -14,4% | |
| 2025-05-02 | Carruthers R Michael | Officer, Chief Financial Officer | Open Market Sale | -1,314 | 16.45 | -21,620.82 | -3,7% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.